ArticleFrontiers in bioengineering and biotechnology2025
Hierarchical biomechanical characterisation of riboflavin-UVA crosslinking and decorin treatment in the porcine cornea.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The mechanisms underpinning the stiffening and stabilising effect of riboflavin/UVA crosslinking on the corneal stroma are not well understood. We report the findings of a biomechanics and synchrotron X-ray scattering study aimed at quantifying hierarchical strain mechanisms in treated and untreated porcine corneas. We applied the same approach to specimens treated with human recombinant decorin core protein, in isolation and in conjunction with riboflavin/UVA. Methods: Tensile testing was carried out in conjunction with simultaneous synchrotron X-ray scattering. Diffraction peaks associated with the interfibrillar spacing and D-period of collagen were fit to bespoke models to quantify fibril elongation and reorientation under load. Results: Riboflavin/UVA crosslinking stiffened corneas by approximately 60% while decorin treatment did not significantly affect the mechanical properties. Correlations between fibril elongation caused by applied tensile strain and bulk stiffness were used to approximate fibril stiffness, values for which were relatively similar for control and treatment groups, compared with the magnitude of difference in the bulk stiffness alone. Discussion: The results imply the bulk stiffening caused by crosslinking was not primarily due to increases in fibril stiffness. Instead, trends in bulk fibril reorientation and straightening/uncrimping imply the stiffening is attributable to enhanced interconnectivity of the fibrillar stroma, leading to greater fibril recruitment fraction. The techniques reported here are applicable to a wide range of tissues for the evaluation of new, existing and adjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.